Headache for Zosano as FDA turns down migraine patchZosano Pharma has been hit by an FDA rejection of its marketing application for migraine drug Qtrypta, asking Share XHeadache for Zosano as FDA turns down migraine patchhttps://pharmaphorum.com/news/headache-for-zosano-as-fda-turns-down-migraine-patch/
Salvia raises 26 million euros to finance migraine neurostimulation therapySalvia BioElectronics has raised 26 million euros ($30 million) in new financing to fund development of a neurostimulation Share XSalvia raises 26 million euros to finance migraine neurostimulation therapyhttps://pharmaphorum.com/news/salvia-raises-26-million-euros-to-finance-migraine-neurostimulation-therapy/
Satsuma pulped as acute migraine drug flunks phase 3 trialShares in California biotech Satsuma Pharma have lost three quarters of their value after lead drug STS01 failed Share XSatsuma pulped as acute migraine drug flunks phase 3 trialhttps://pharmaphorum.com/news/satsuma-pulped-as-acute-migraine-drug-flunks-phase-3-trial/
Lundbeck announces plans to cut a fifth of R&D workforceLundbeck has announced plans to cut its research and development team, which could lead to a reduction of Share XLundbeck announces plans to cut a fifth of R&D workforcehttps://pharmaphorum.com/news/lundbeck-announces-plans-to-cut-around-160-rd-jobs/
After rejecting Novartis’ Aimovig for migraine, NICE backs Teva rival AjovySeveral months after turning down NHS funding for Novartis’ CGRP inhibitor Aimovig for migraine prevention, NICE has backed Share XAfter rejecting Novartis’ Aimovig for migraine, NICE backs Teva rival Ajovyhttps://pharmaphorum.com/news/novartis-aimovig-for-migraine-nice-backs-teva-rival/
FDA approves ‘potential blockbuster’ migraine jab from LundbeckThe FDA has approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs Share XFDA approves ‘potential blockbuster’ migraine jab from Lundbeckhttps://pharmaphorum.com/news/fda-approves-potential-blockbuster-migraine-jab-from-lundbeck/
After rejection, NICE agrees to look again at migraine drug AimovigThe UK’s medicines cost-effectiveness agency NICE has agreed to look again at its decision to turn down NHS Share XAfter rejection, NICE agrees to look again at migraine drug Aimovighttps://pharmaphorum.com/news/nice-migraine-aimovig/
FDA approves Allergan’s migraine tablet ahead of AbbVie mergerAllergan’s migraine tablet Ubrelvy (ubrogepant) has been approved in the US for the acute treatment of patients with Share XFDA approves Allergan’s migraine tablet ahead of AbbVie mergerhttps://pharmaphorum.com/news/fda-approves-allergans-migraine-tablet-ahead-of-abbvie-merger/
Allergan builds case for migraine drug ubrogepant as FDA verdict nearsAllergan’s ubrogepant could become the first oral drug in the new CGRP inhibitor class if it is approved Share XAllergan builds case for migraine drug ubrogepant as FDA verdict nearshttps://pharmaphorum.com/news/allergan-builds-case-for-migraine-drug-ubrogepant-as-fda-verdict-nears/
